<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25872590</article-id><article-id pub-id-type="pmc">4381488</article-id><article-id pub-id-type="publisher-id">622</article-id><article-id pub-id-type="doi">10.1186/s13063-015-0622-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Laser therapy for onychomycosis in patients with diabetes at risk for foot complications: study protocol for a randomized, double-blind, controlled trial (LASER-1)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nijenhuis-Rosien</surname><given-names>Leonie</given-names></name><address><email>l.nijenhuis@isala.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kleefstra</surname><given-names>Nanne</given-names></name><address><email>n.kleefstra@isala.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Wolfhagen</surname><given-names>Maurice J</given-names></name><address><email>m.j.h.m.wolfhagen@isala.nl</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Groenier</surname><given-names>Klaas H</given-names></name><address><email>k.h.groenier@umcg.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Bilo</surname><given-names>Henk JG</given-names></name><address><email>h.j.g.bilo@isala.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Landman</surname><given-names>Gijs WD</given-names></name><address><email>g.w.d.landman@isala.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff7"/></contrib><aff id="Aff1"><label/>Diabetes Centre, Isala, Dr Spanjaardweg 11, 8025 BT Zwolle, the Netherlands </aff><aff id="Aff2"><label/>Innofeet Voetencentrum Nijenhuis Podiatry, Simon Stevinweg 13, 8013 NA Zwolle, the Netherlands </aff><aff id="Aff3"><label/>Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands </aff><aff id="Aff4"><label/>Langerhans Medical Research Group, Postbus 21, 4254 ZG Sleeuwijk, the Netherlands </aff><aff id="Aff5"><label/>Department of Medical Microbiology, Isala, Dr. van Heesweg 2 8025 AB Zwolle, the Netherlands </aff><aff id="Aff6"><label/>Department of General Practice, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands </aff><aff id="Aff7"><label/>Department of Internal Medicine, Gelre Hospital, Albert Schweitzerlaan 31, 7334 DZ Apeldoorn, the Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>108</elocation-id><history><date date-type="received"><day>27</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Nijenhuis-Rosien et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>In a sham-controlled double-blind trial, we aim to establish the efficacy and safety of the local application of laser therapy in patients with diabetes, onychomycosis and risk factors for diabetes-related foot complications. Onychomycosis leads to thickened and distorted nails, which in turn lead to increased local pressure. The combination of onychomycosis and neuropathy or peripheral arterial disease (PAD) increases the risk of developing diabetes-related foot complications. Usual care for high-risk patients with diabetes and onychomycosis is completely symptomatic with frequent shaving and clipping of the nails. No effective curative local therapies exist, and systemic agents are often withheld due to concerns for side effects and interactions.</p></sec><sec><title>Methods/Design</title><p>The primary aim is to evaluate the efficacy of four sessions of Nd:YAG 1064 nM laser application on the one-year clinical and microbiological cure rate in a randomized, double-blind, sham-controlled design with blinded outcome assessment. Mandatory inclusion criteria are diagnosis of diabetes, risk factors for developing foot ulcers defined as a modified Simm&#x02019;s classification score 1 or 2 and either neuropathy or PAD. A total of 64 patients are randomized to intervention or sham treatment performed by a podiatrist.</p></sec><sec><title>Discussion</title><p>This study will be the first double-blind study that investigates the effects of local laser therapy on onychomycosis, specifically performed in patients with diabetes with additional risk factors for foot complications.</p></sec><sec><title>Trial registration</title><p>Clinical trials.gov as <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT01996995">NCT01996995</ext-link>, first received 22 November 2013.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Onychomycosis</kwd><kwd>Nd:YAG laser</kwd><kwd>Diabetic foot</kwd><kwd>Diabetic foot ulcer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>The prevalence of onychomycosis is 2.5 to 2.8 times higher in patients with diabetes [<xref ref-type="bibr" rid="CR1">1</xref>-<xref ref-type="bibr" rid="CR3">3</xref>]. The combination of onychomycosis with other risk factors, like neuropathy, increases the risk of developing diabetes-related foot complications [<xref ref-type="bibr" rid="CR4">4</xref>]. Onychomycosis leads to thickening and sharpening of the nails. Thickening of the nails potentially increases subungual pressure and compromises vascular flow [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref>]. Sharpening of the nails can lead to small skin injuries, which are potential portals of entry for pathogens. In the presence of neuropathy and/or peripheral arterial disease (PAD), onychomycosis is an additive risk factor for diabetes-related foot complications like foot ulcers, cellulitis, osteomyelitis and gangrene [<xref ref-type="bibr" rid="CR7">7</xref>-<xref ref-type="bibr" rid="CR10">10</xref>]. Worldwide, foot ulcers in patients with diabetes are the leading cause of hospitalizations and amputations [<xref ref-type="bibr" rid="CR11">11</xref>-<xref ref-type="bibr" rid="CR15">15</xref>]. The development of foot ulcers has been associated with considerable disability [<xref ref-type="bibr" rid="CR16">16</xref>-<xref ref-type="bibr" rid="CR18">18</xref>], and the presence of onychomycosis has been associated with various emotional and social problems [<xref ref-type="bibr" rid="CR19">19</xref>-<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>Treating onychomycosis is increasingly recognized as a potential strategy for preventing diabetes-related foot complications [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR24">24</xref>-<xref ref-type="bibr" rid="CR26">26</xref>]. As part of the national Dutch foot care program, usual care for patients with onychomycosis is symptomatic; every six weeks, nails are skived to normal proportions and sharp edges are clipped and removed. This podiatric treatment aims to prevent ulcer formation and the development of infections through reducing subungual pressure and sharpen nails. Although effective systemic antifungal agents are available, they are often withheld due to concerns of side effects and interactions [<xref ref-type="bibr" rid="CR27">27</xref>]. Furthermore, studies that investigated antifungal agents mostly excluded patients with diabetes. Despite many claims of efficacy, no proven effective local therapies exist. An effective and safe curative treatment option for onychomycosis could lead to a decrease in diabetes-related foot complications, especially in patients with other risk factors. By reducing the frequency of &#x02018;skiving and clipping&#x02019; treatment sessions and by reducing the development of ulcers and infections caused by treatment-resistant onychomycosis, local therapies could become valuable preventive treatment option [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p>Local laser therapy is becoming increasingly popular as a treatment modality for a variety of dermatologic conditions and is being applied in the treatment of onychomycosis [<xref ref-type="bibr" rid="CR29">29</xref>]. The use of lasers for improving toenail appearance has become one of the most rapidly approved therapies by the US Food and Drug Administration (FDA) [<xref ref-type="bibr" rid="CR29">29</xref>]. Unlike pharmacologic agents, laser systems are presumed to have predictable adverse effects [<xref ref-type="bibr" rid="CR29">29</xref>]. There are few nonrandomized trials and very few randomized studies investigating effect of laser therapy on onychomycosis. None had a double-blind design, and none were performed in patients with diabetes who also had additional risk factors for foot ulcers [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>The primary aim of this trial is to evaluate the efficacy of four sessions of N-YAG 1064nM laser application on the one-year complete cure rate of onychomycosis in patients with diabetes and risk factors for developing diabetes related foot complications. Secondary outcomes are microbiologic cure rate and improvement in health-related quality of life (HRQOL).</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods/Design</title><p>Primary and secondary care patients with type 1 and type 2 diabetes mellitus with risk factors for developing diabetic foot ulcers and a clinical suspicion of onychomycosis will be recruited from a single-center podiatry practice. Patients will be included after written informed consent and microbiologic confirmation of onychomycosis.</p><p>Nail dust is collected from the target nail for microbiologic confirmation with blankophor microscopy, culture and polymerase chain reaction (PCR). PCR is regarded as the gold standard. The PCR is a real-time multiplex PCR based on amplification of ribosomal internal transcribed spacer regions and identification by probes specific for <italic>Trichophyton mentagrophytes</italic> species complex, <italic>Trichophyton tonsurans</italic>, <italic>Trichophyton violaceum</italic>, <italic>Trichophyton rubrum</italic> species complex, <italic>Microsporum canis</italic>, <italic>Microsporum audouinii</italic> and <italic>Epidermophyton floccosum</italic> as described by Arabatzis <italic>et al.</italic> [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>The target nail is the nail with the highest onychomycosis severity index. The severity of onychomycosis is evaluated with the onychomycosis severity index (OSI) and standardized photographs are made [<xref ref-type="bibr" rid="CR31">31</xref>]. Evaluation of treatment results will be done by an independent expert panel blinded for treatment allocation. The three experts are experienced health care providers who have experience in the treatment of patients with diabetic foot problems. Health-related quality of life (HRQOl) is evaluated at baseline and after follow-up with a generic questionnaire, the WHO-5, and a disease specific questionnaire the NailQOl [<xref ref-type="bibr" rid="CR23">23</xref>]. The trial has received research ethics board approval from METC Isala Zwolle (NL46084.075.13/METC nr 13.0885).</p><sec id="Sec3"><title>Study endpoints</title><p>The primary endpoint is complete cure rate of the target nail. Complete cure is defined as a completely normal nail, or negative microbiological results in case minor abnormalities are present. A minor abnormality is defined as an irregularity of the nails with less than 5% of the surface area of the target nail at less than 1/4 of the distance of the distal nail edge without hyperkeratosis. Secondary endpoints are microbiologic cure rate of the target nail, complete clinical cure of all affected toes, complete clinical cure of the target nail, markedly clinically improvement of the target nail, onychomycosis severity index below 6 (in patients with scores &#x0003e;6 at study entry) of the target nail, changes in the affected surface of the target nail, changes in affected surface of all nails with a clinical diagnose of infection, free of subungual hyperkeratosis and changes in HRQOL. A &#x02018;markedly clinical nail improvement&#x02019; is defined as a nail with less than 10% abnormalities and without hyperkeratosis after 52&#x000a0;weeks.</p></sec><sec id="Sec4"><title>Patient selection criteria</title><p>Patients with clinical suspicion and microbiologic confirmation of onychomycosis are randomized to laser treatment or sham, see Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Study flow chart.</bold>
</p></caption><graphic xlink:href="13063_2015_622_Fig1_HTML" id="MO1"/></fig></p><p>Mandatory inclusion criteria are diagnosis of T1DM or T2DM, 18&#x000a0;years or older, at risk for diabetic foot ulcers defined by a modified Simm&#x02019;s classification score 1 or 2 with either neuropathy or PAD [<xref ref-type="bibr" rid="CR32">32</xref>], and nail involvement of at least 25% of the target nail [<xref ref-type="bibr" rid="CR3">3</xref>]. See Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> for the modified Simm&#x02019;s classification.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>The modified Simms&#x02019; classification</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Simm&#x02019;s classification</bold>
</th><th>
<bold>Risk profile</bold>
</th><th>
<bold>Control frequency</bold>
</th></tr></thead><tbody><tr valign="top"><td>Simm&#x02019;s 0</td><td>No loss of PS or PAV</td><td>Once in 12&#x000a0;months</td></tr><tr valign="top"><td>Simm&#x02019;s 1</td><td>Loss of PS or PAD, Without signs of local increased pressure</td><td>Once in 6&#x000a0;months</td></tr><tr valign="top"><td>Simm&#x02019;s 2</td><td>Loss of PS and PAD. Loss of PS and/or PAD in combination with signs of local increased pressure.</td><td>Once in 3&#x000a0;months</td></tr><tr valign="top"><td>Simm&#x02019;s 3</td><td>Ulcer or amputation in the medical history</td><td>Once in 1 to 3&#x000a0;months</td></tr></tbody></table><table-wrap-foot><p>PAD, peripheral arterial disease; PS, protective sensibility.</p></table-wrap-foot></table-wrap></p><p>Exclusion criteria are no microbiologic confirmation, Simms&#x02019; classification score 3, the presence or history of diabetic foot ulcers, ischemic pain, ankle brachial index &#x0003c;0.9, patients receiving dialysis, severe renal insufficiently (eGFR below 30&#x000a0;ml/min), a documented toe pressure below 50&#x000a0;mmHg, use of systemic or topical antifungal agents 3&#x000a0;months prior to inclusion, use of immunosuppressive drugs, presence of psoriasis, lichen planus, or other abnormalities that could result in clinically abnormal toenails, a history of epilepsy and insufficient knowledge of the Dutch language. Patients with a dark skin color (Fitzpatrick 4 and 5) are excluded since dark skin color is associated with dark nails, which theoretically lead to increased temperatures during laser application [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec5"><title>Treatment assignment</title><p>Patients will be randomized in blocks using sealed nontransparent envelopes to either laser or sham treatment. A cloth between the head and his or her feet and a blinded goggle (which also protects the eyes) is used for blinding the subjects. The periprocedural sounds and lights during the laser application and the sham procedure are identical. The investigators are blinded for treatment allocation through the use of an independent second podiatrist who performs the interventions. An independent three-person panel blinded for treatment allocation evaluates the study outcomes using standardized photographs made at baseline, week 30 and at the end of follow-up. When consensus cannot be reached, decisions are made through majority voting.</p></sec><sec id="Sec6"><title>Clinical follow-up</title><p>Patients are treated with laser session in week 0, 2, 4, and 12. The settings are<italic>;</italic> 1064&#x000a0;nm, spot size 3&#x000a0;mm, 20&#x000a0;J /cm2, 5&#x000a0;Hz, power 10&#x000a0;W. A maximum of two sequential sessions (one session on the horizontal and one the vertical passing) will be applied to eliminate potential safety issues in those patients with a lack protective sensibility.</p><p>After 52&#x000a0;weeks, complete regrowth of the nail can be expected. At baseline, 30 and 52&#x000a0;weeks all target nails are sampled for blankophor microscopy, culture and polymerase chain reaction.</p><p>At baseline, 30 and 52&#x000a0;weeks, all nails are evaluated using the following scale: completely healed, markedly improved (less than 10% affected), minor improvement, unchanged, and worse, and with the onychomycosis severity index [<xref ref-type="bibr" rid="CR31">31</xref>]. The microbiological outcomes from week 30 are used to differentiate re-infection from persistent infection. Patients with re-infection have negative microbiological results at week 30 and positive results at week 52. Patients in whom different organisms at baseline and week 30 or 52 are isolated are regarded as having a reinfection. Patients are regarded as having a persistent infection when baseline, week 30 and week 52 microbiological results provide evidence of the same organism. Week 52 results, including the microbiological results, are used for evaluation of the primary and secondary outcomes. See Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> for the follow-up survey.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Follow-up survey</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="2"/><th rowspan="2">
<bold>Baseline</bold>
</th><th>
<bold>Week 0</bold>
</th><th>
<bold>Week 2</bold>
</th><th>
<bold>Week 4</bold>
</th><th>
<bold>Week 12</bold>
</th><th>
<bold>Week 30</bold>
</th><th>
<bold>Week 52</bold>
</th></tr><tr valign="top"><th>
<bold>Session 1</bold>
</th><th>
<bold>Session 2</bold>
</th><th>
<bold>Session 3</bold>
</th><th>
<bold>Session 4</bold>
</th><th/><th/></tr></thead><tbody><tr valign="top"><td>Inclusion</td><td/><td>x</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>Randomization</td><td/><td>x</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>Blankophor microscopy/Culture</td><td>X</td><td/><td/><td/><td/><td>x</td><td>X</td></tr><tr valign="top"><td>/PCR</td><td/><td/><td/><td/><td/><td/><td/></tr><tr valign="top"><td>Photo</td><td>X</td><td/><td/><td/><td>x</td><td>x</td><td>X</td></tr><tr valign="top"><td>Treatment</td><td/><td>x</td><td>x</td><td>x</td><td>x</td><td/><td/></tr></tbody></table></table-wrap></p></sec><sec id="Sec7"><title>Data analysis</title><p>Estimating the proportion of patients with a complete cure rate to be 40% in the intervention group and 5% in the control group [<xref ref-type="bibr" rid="CR27">27</xref>], with a power of 0.85, an alpha of 0.05 (2-tailed), the sample size should be at least 56. Accounting for loss to follow-up, the total sample size will be aimed at 64.</p><p>Data entry is done in duplicate by persons not otherwise involved in the study. All statistical analyses are carried out by a statistician blinded for treatment allocation. The Fisher&#x02019;s Exact test will be used to test for differences between the treatment groups, and 95% confidence intervals (CIs) will be constructed for the differences in clinical and microbial cure rates. Normally distributed continuous variables will be compared using the Student <italic>t</italic>-test, and non-normally distributed variables will be compared with the Mann-Whitney <italic>U</italic> test. A significance level of less than 5% is regarded as significant. Analyses will be performed according to the intention-to-treat principle. Separate per-protocol analyses are planned in patients in whom all treatment sessions are performed and for analyses excluding re-infection. A sensitivity analysis is planned that regards completely cured patients at week 30 who have a new infection at week 52 as having a complete cure. All endpoints are evaluated at week 52.</p></sec></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>Patients with diabetes who suffer from onychomycosis and neuropathy or PAD have an increased risk for developing diabetes-related foot complications, but also for treatment-related complications. New, effective and safe treatment modalities are needed for patients with diabetes who have risk factors for diabetes-related foot complications, in order to minimize the risks of developing ulcers and also to minimize discomfort and treatment-related complications caused by the current usual care.</p><p>The results of this study will provide the first double-blinded evidence for laser therapy and the first study in patients with diabetes mellitus with risk factors for developing diabetic foot ulcers. Positive results could aid in the prevention of diabetes-related foot complications since no local curative options are available, and systemic treatment could be avoided. If the results were to show safety and efficacy of laser therapy, this would provide the first high-level evidence for efficacy of a local treatment modality against onychomycosis. The results of this study will be at least equally relevant if they were to show non-efficacy since the use of lasers is becoming increasingly popular. In that case, unnecessary laser applications and possible harm could be avoided.</p></sec><sec id="Sec9"><title>Trial status</title><p>Recruiting.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CI</term><def><p>confidence intervals</p></def></def-item><def-item><term>FDA</term><def><p>Food and Drug Administration</p></def></def-item><def-item><term>HRQOL</term><def><p>health-related quality of life</p></def></def-item><def-item><term>OSI</term><def><p>Onychomycosis Severity Index</p></def></def-item><def-item><term>PAD</term><def><p>peripheral arterial disease</p></def></def-item><def-item><term>PCR</term><def><p>polymerase chain reaction</p></def></def-item><def-item><term>QoL</term><def><p>quality of life</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>One of the employers of L. Nijenhuis has a stake in a company that supplies medical devices, among others, the laser used for this study, L. Nijenhuis has no stake in this company. All other authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>GL and NK conceived the study. GL, LN and NK developed the study protocol. HB, MW, KG made critical revisions to the manuscript. MW supervises the microbiological study. KG performed the statistical planning. All authors have reviewed and approved the final version of the manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The Hein Hogerzeil foundation funded starting costs and microbiological costs in the form of a grant. The Dutch Diabetes Research Foundation has awarded a grant for this study (grant nr. 2014.00.1741).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Van Gaal</surname><given-names>L</given-names></name><name><surname>Lucioni</surname><given-names>C</given-names></name></person-group><article-title>Assessing the impact of complications on the costs of Type II diabetes</article-title><source>Diabetologia</source><year>2002</year><volume>45</volume><fpage>S13</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00125-002-0859-9</pub-id><pub-id pub-id-type="pmid">12136406</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulton</surname><given-names>AJ</given-names></name><name><surname>Vinik</surname><given-names>AI</given-names></name><name><surname>Arezzo</surname><given-names>JC</given-names></name><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name><etal/></person-group><article-title>Diabetic neuropathies: a statement by the American Diabetes Association</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>956</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.4.956</pub-id><pub-id pub-id-type="pmid">15793206</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Konnikov</surname><given-names>N</given-names></name><name><surname>MacDonald</surname><given-names>P</given-names></name><name><surname>Rich</surname><given-names>P</given-names></name><name><surname>Rodger</surname><given-names>N</given-names></name><name><surname>Edmonds</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicenter study</article-title><source>Br J Dermatol</source><year>1998</year><volume>139</volume><fpage>665</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.1998.02464.x</pub-id><pub-id pub-id-type="pmid">9892911</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyko</surname><given-names>E</given-names></name><name><surname>Ahroni</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>V</given-names></name><name><surname>Nelson</surname><given-names>K</given-names></name><name><surname>Heagerty</surname><given-names>P</given-names></name></person-group><article-title>Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the seattle Diabetic Foot Study</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1202</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2337/dc05-2031</pub-id><pub-id pub-id-type="pmid">16731996</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cathcart</surname><given-names>S</given-names></name><name><surname>Cantrell</surname><given-names>W</given-names></name><name><surname>Elewski</surname><given-names>B</given-names></name></person-group><article-title>Onychomycosis and diabetes</article-title><source>J Eur Acad Dermatol Venereol</source><year>2009</year><volume>23</volume><fpage>1119</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/j.1468-3083.2009.03225.x</pub-id><pub-id pub-id-type="pmid">19309423</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname><given-names>P</given-names></name></person-group><article-title>Onychomycosis and tinea pedis in patients with diabetes</article-title><source>J Am Acad Dermatol</source><year>2000</year><volume>43</volume><fpage>130</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1067/mjd.2000.110376</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Holtz</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name></person-group><article-title>Can the use of a topical antifungal nail lacquer reduce risk for diabetic foot ulceration? results from a randomised controlled pilot study</article-title><source>Int Wound J</source><year>2005</year><volume>2</volume><fpage>166</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4801.2005.00097.x</pub-id><pub-id pub-id-type="pmid">16722866</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodell</surname><given-names>J</given-names></name><name><surname>Brodell</surname><given-names>R</given-names></name></person-group><article-title>Recurrent lymphangitic ellulitis syndrome</article-title><source>Contemp Orthop</source><year>1992</year><volume>25</volume><fpage>461</fpage><lpage>8</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>N</given-names></name><name><surname>Colver</surname><given-names>G</given-names></name><name><surname>Paterson</surname><given-names>W</given-names></name></person-group><article-title>Management and morbidity of cellulitis of the leg</article-title><source>J R Soc Med</source><year>1998</year><volume>91</volume><fpage>634</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10730111</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>R</given-names></name><name><surname>Daugird</surname><given-names>A</given-names></name></person-group><article-title>Recurrent leg cellulitis: pathogenesis, prevention and treatment</article-title><source>J Am Board Fam Pract</source><year>1992</year><volume>5</volume><fpage>85</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1561927</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>D</given-names></name></person-group><article-title>Is diabetic foot care efficacious or cost-effective?</article-title><source>Ostomy Wound Manage</source><year>2001</year><volume>47</volume><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11890086</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bild</surname><given-names>D</given-names></name><name><surname>Shelby</surname><given-names>J</given-names></name><name><surname>Sinnock</surname><given-names>P</given-names></name><name><surname>Browner</surname><given-names>W</given-names></name><name><surname>Braveman</surname><given-names>P</given-names></name><name><surname>Showstock</surname><given-names>J</given-names></name></person-group><article-title>Lower extremity amputations in people with diabetes: epidemiology and prevention</article-title><source>Diabetes Care</source><year>1989</year><volume>12</volume><fpage>24</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2337/diacare.12.1.24</pub-id><pub-id pub-id-type="pmid">2714164</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>P</given-names></name></person-group><article-title>The diabetic foot ulcer: a complex problem with a simple treatment approach</article-title><source>Mil Med</source><year>1981</year><volume>146</volume><fpage>644</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6793913</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavery</surname><given-names>L</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Vela</surname><given-names>S</given-names></name><name><surname>Quebedeaux</surname><given-names>T</given-names></name><name><surname>Fleischli</surname><given-names>J</given-names></name></person-group><article-title>Practical criteria for screening patients at high risk for diabetic foot ulceration</article-title><source>Arch Intern Med</source><year>1998</year><volume>158</volume><fpage>158</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1001/archinte.158.2.157</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Weinberger</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>B</given-names></name></person-group><article-title>A controlled trial to increase office visits and reduce hospitalization in diabetic patients</article-title><source>J Gen Intern Med</source><year>1987</year><volume>2</volume><fpage>232</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF02596446</pub-id><pub-id pub-id-type="pmid">3612344</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Humke</surname><given-names>S</given-names></name></person-group><article-title>The prevalence and management of onychomycosis in diabetic patients</article-title><source>Eur J Dermatol</source><year>2000</year><volume>10</volume><fpage>379</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">10882947</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karchmer</surname><given-names>A</given-names></name><name><surname>Gibbons</surname><given-names>G</given-names></name></person-group><article-title>Foot infection in diabetes: evaluation and management</article-title><source>Curr Clin Top Infect Dis</source><year>1994</year><volume>14</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">8086109</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Blough</surname><given-names>D</given-names></name><name><surname>McCulloch</surname><given-names>D</given-names></name><name><surname>Sandhu</surname><given-names>N</given-names></name><name><surname>Reiber</surname><given-names>G</given-names></name><etal/></person-group><article-title>Incidence, outcomes, and cost of foot ulcers in patients with diabetes</article-title><source>Diabetes Care</source><year>1999</year><volume>22</volume><fpage>383</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2337/diacare.22.3.382</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuster</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>GH</given-names></name><name><surname>Harris</surname><given-names>E</given-names></name><name><surname>Binnell</surname><given-names>D</given-names></name></person-group><article-title>The effect of skin disease on self image [proceedings]</article-title><source>Br J Dermatol</source><year>1978</year><volume>99</volume><fpage>18</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1978.tb15214.x</pub-id><pub-id pub-id-type="pmid">151549</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuster</surname><given-names>S</given-names></name></person-group><article-title>Depression of self-image by skin disease</article-title><source>Acta Derm Venereol Suppl (Stockh)</source><year>1991</year><volume>156</volume><fpage>53</fpage><pub-id pub-id-type="pmid">2048378</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>LA</given-names></name><name><surname>Scher</surname><given-names>RK</given-names></name><name><surname>Smith</surname><given-names>EB</given-names></name><name><surname>Faich</surname><given-names>GA</given-names></name><name><surname>Smith</surname><given-names>SL</given-names></name><name><surname>Hong</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Effect of onychomycosis on quality of life</article-title><source>J Am Acad Dermatol</source><year>1998</year><volume>38</volume><fpage>702</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0190-9622(98)70199-9</pub-id><pub-id pub-id-type="pmid">9591814</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>LA</given-names></name><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Fleckman</surname><given-names>P</given-names></name><name><surname>Andr</surname><given-names>J</given-names></name><name><surname>Baran</surname><given-names>R</given-names></name><name><surname>Haneke</surname><given-names>E</given-names></name><etal/></person-group><article-title>The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life</article-title><source>J Am Acad Dermatol</source><year>1999</year><volume>41</volume><fpage>189</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S0190-9622(99)70047-2</pub-id><pub-id pub-id-type="pmid">10426887</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warshaw</surname><given-names>EM</given-names></name><name><surname>Foster</surname><given-names>JK</given-names></name><name><surname>Cham</surname><given-names>PM</given-names></name><name><surname>Grill</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name></person-group><article-title>NailQoL: a quality-of-life instrument for onychomycosis</article-title><source>Int J Dermatol</source><year>2007</year><volume>46</volume><fpage>1279</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1111/j.1365-4632.2007.03362.x</pub-id><pub-id pub-id-type="pmid">18173524</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>J</given-names></name></person-group><article-title>Treatment of onychomycosis in the diabetic population</article-title><source>J Diabetes Complications</source><year>2003</year><volume>17</volume><fpage>98</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/S1056-8727(02)00199-X</pub-id><pub-id pub-id-type="pmid">12614976</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apelqvist</surname><given-names>J</given-names></name><name><surname>Larrson</surname><given-names>J</given-names></name></person-group><article-title>What is the most effective way to reduce incidence of amputation in the diabetic foot?</article-title><source>Diabetes Metab Res Rev</source><year>2000</year><volume>16</volume><fpage>s75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1002/1520-7560(200009/10)16:1+&#x0003c;::AID-DMRR139&#x0003e;3.0.CO;2-8</pub-id><pub-id pub-id-type="pmid">11054894</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Lipsky</surname><given-names>B</given-names></name></person-group><article-title>Preventing foot ulcers in patients with diabetes</article-title><source>J Am Med Assoc</source><year>2005</year><volume>293</volume><fpage>217</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1001/jama.293.2.217</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Simpson</surname><given-names>FC</given-names></name></person-group><article-title>New therapeutic options for onychomycosis</article-title><source>Expert Opin Pharmacother</source><year>2012</year><volume>13</volume><fpage>1131</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1517/14656566.2012.681779</pub-id><pub-id pub-id-type="pmid">22533461</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anarella</surname><given-names>J</given-names></name><name><surname>Toth</surname><given-names>C</given-names></name><name><surname>Debello</surname><given-names>J</given-names></name></person-group><article-title>Preventing complications in the diabetic patient with toenail onychomycosis</article-title><source>J Am Podiatr Med Assoc</source><year>2001</year><volume>91</volume><fpage>325</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.7547/87507315-91-6-325</pub-id><pub-id pub-id-type="pmid">11420354</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatta</surname><given-names>AK</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Keyal</surname><given-names>U</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name></person-group><article-title>Laser treatment for onychomycosis: a review</article-title><source>Mycoses</source><year>2014</year><volume>57</volume><fpage>734</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/myc.12225</pub-id><pub-id pub-id-type="pmid">25100500</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabatzis</surname><given-names>M</given-names></name><name><surname>van Coppenraet</surname><given-names>LEB</given-names></name><name><surname>Kuijper</surname><given-names>EJ</given-names></name><name><surname>de Hoog</surname><given-names>GS</given-names></name><name><surname>Lavrijsen</surname><given-names>AP</given-names></name><name><surname>Templeton</surname><given-names>K</given-names></name><etal/></person-group><article-title>Diagnosis of common dermatophyte infections by a novel multiplex real-time polymerase chain reaction detection/identification scheme</article-title><source>Br J Dermatol</source><year>2007</year><volume>157</volume><fpage>681</fpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2007.08100.x</pub-id><pub-id pub-id-type="pmid">17672875</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carney</surname><given-names>C</given-names></name><name><surname>Tosti</surname><given-names>A</given-names></name><name><surname>Daniel</surname><given-names>R</given-names></name><name><surname>Scher</surname><given-names>R</given-names></name><name><surname>Rich</surname><given-names>P</given-names></name><name><surname>DeCoster</surname><given-names>J</given-names></name><etal/></person-group><article-title>A new classification system for grading the severity of onychomycosis: Onychomycosis Severity Index</article-title><source>Arch Dermatol</source><year>2011</year><volume>147</volume><fpage>1277</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1001/archdermatol.2011.267</pub-id><pub-id pub-id-type="pmid">22106113</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Nederlandse Internisten Vereeniging. Richtlijn Diabetische voet. Van Zuiden Communications B.V., Alphen aan den Rijn, ISBN-10 90-8523-142-6, 2007.</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>K</given-names></name><name><surname>Sankar</surname><given-names>TK</given-names></name></person-group><article-title>Long-pulsed Nd:YAG laser-assisted hair removal in Fitzpatrick skin types IV-VI</article-title><source>Lasers Med Sci</source><year>2011</year><volume>26</volume><fpage>623</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s10103-011-0922-1</pub-id><pub-id pub-id-type="pmid">21519944</pub-id></element-citation></ref></ref-list></back></article>